Full Year 2024 Fresenius SE & Co KGaA Earnings Call Transcript
Key Points
- Fresenius SE & Co KGaA (FSNUF) achieved high single-digit organic revenue growth and double-digit EBIT growth in 2024.
- The company successfully executed strategic portfolio measures, including divesting non-core assets and deconsolidating Fresenius Medical Care.
- Fresenius SE & Co KGaA (FSNUF) reported a significant improvement in EPS, with a 14% growth in 2024 compared to a 13% decline in 2022.
- The biopharma segment showed impressive growth, with a 76% year-over-year revenue increase, contributing significantly to the company's overall performance.
- The company resumed its dividend payments, proposing EUR1 per share for 2024, reflecting its improved financial strength and commitment to shareholder value.
- The macroeconomic environment remains volatile, with global markets experiencing rapid changes and shifting trade dynamics.
- Fresenius SE & Co KGaA (FSNUF) faces challenges in China due to a slower economic situation and the impact of national volume-based procurement policies.
- The company anticipates a negative impact on performance in Q2 2025 due to the inclusion of keto in China's national volume-based procurement process.
- Helios Germany faces headwinds from the ending of energy relief payments, which will impact year-over-year comparisons.
- The company acknowledges that achieving its ambitious targets will require overcoming significant operational challenges and uncertainties.
Good afternoon and welcome to the conference call of Fresenius' Investor Relations, which is now starting. May I hand you over to Nick Stone, Head of Investor Relations.
Thank you, operator. Hello everyone. Welcome to our full year in Q4 2024 earnings call and web. The presentation was emailed to our distribution list earlier today and is available on fresenius.com. On slide 2 of the presentation, you'll find the usual safe harbor statements unless stated otherwise, we'll comment on our performance using constant exchange rates or CER.
Today I'm joined by Michael and Sarah, who will take you through the details of another strong performance. The call will last approximately one hour, with the presentation taking around 35 minutes and the remaining time for your questions. To give everyone the chance to participate, please limit your questions to one to two in the first instance. We can always come back for a second round if needed.
And with that, I will now
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
